Can anticancer chemotherapy promote the progression of brain metastases?
Brain metastases natural history from one primary tumor type might be accelerated or favored by using certain systemic chemotherapy. A great deal was described in mice and suggested in human with antiangiogenic drugs, but little is known about the metastatic progression generated by the perverse effect of anticancer drugs. A total of 413 patients who underwent treatment for brain metastasis (2013–2016) were included. The identification of all previous anticancer drugs received by patients from primary tumor diagnosis to brain metastases diagnosis was collated. The median value for the time of first appearance of brain metastasis in all patients was 13.1 months (SD 1.77). The values of brain metastasis-free survival (bMFS) for each primary cancer were: 50.9 months (SD 8.8) for breast, 28.5 months (SD 11.4) for digestive, 27.7 months (SD 18.3) for melanoma, 12.3 months (SD 8.3) for kidney, 1.5 months (SD 0.1) for lung and 26.9 months (SD 18.3) for others (p < 0.009). Through Cox multivariate proportional hazard model, we identified that the only independent factors associated with short bMFS were: lung primary tumor [odd ratio (OR) 0.234, CI 95% 0.16–0.42; p < 0.0001] and mitotic spindle inhibitor (taxanes) chemotherapy [OR 0.609, CI 95% 0.50–0.93; p < 0.001]. Contrariwise, breast primary tumor [odd ratio (OR) 2.372, CI 95% 1.29–4.3; p < 0.005] was an independent factor that proved a significantly longer bMFS. We suggest that anticancer drugs, especially taxane and its derivatives, could promote brain metastases, decreasing free survival. Mechanisms are discussed but still need to be determined.
KeywordsBrain metastases Chemotherapy Survival Anticancer drug
AA, LMT, BM, CAV, AC, ML and JJM contributed to design and conceptualization of the study; AA, LMT, ARC, CAV and PC analyzed the data; AA, BM, ARC, LMT, AC, ML and JJM interpreted the data; AA, LMT, AC, ML, JJM and PC drafted the manuscript; AA, LMT, AC, ML and ARC wrote the manuscript; AA, BM, ARC, LMT, CAV, AC, ML, JJM and ARC contributed to manuscript revision for intellectual content. The guarantors, AA and ML are responsible for the overall content.
This study was not funded.
Compliance with Ethical Standards
Conflict of interest
AA, LMT, BM, JJM, CAV, PC, AC and ML declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors. Informed consent was obtained from all individual participants included in the study.
- 3.Posner JB. Neurologic complications of cancer. Philadelphia: FA Davies; 1995.Google Scholar
- 11.Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655–61. https://doi.org/10.1016/j.ijrobp.2009.08.025 Epub 2009 Nov 26.CrossRefPubMedGoogle Scholar
- 12.Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419–25. https://doi.org/10.1200/JCO.2011.38.0527 Epub 2011 Dec 27.CrossRefPubMedGoogle Scholar
- 14.Niwińska A, Rudnicka H, Murawska M. Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival. Med Oncol. 2013;30(1):408. https://doi.org/10.1007/s12032-012-0408-4 Epub 2013 Jan 16.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Enders F, Geisenberger C, Jungk C, Bermejo JL, Warta R, von Deimling A, et al. Prognostic factors and long-term survival in surgically treated brain metastases from non-small cell lung cancer. Clin Neurol Neurosurg. 2016;142:72–80. https://doi.org/10.1016/j.clineuro.2016.01.011 Epub 2016 Jan 14.CrossRefPubMedGoogle Scholar
- 31.Alishekevitz D, Gingis-Velitski S, Kaidar-Person O, Gutter-Kapon L, Scherer SD, Raviv Z, et al. Macrophage-induced lymphangiogenesis and metastasis following paclitaxel chemotherapy is regulated by VEGFR3. Cell Rep. 2016;17(5):1344–56. https://doi.org/10.1016/j.celrep.2016.09.083.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomized controlled trials. Lancet Oncol. 2011;12:236–44.CrossRefPubMedGoogle Scholar